Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sojung | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Kim, Dojin | - |
dc.contributor.author | Sim, Yun Su | - |
dc.contributor.author | Ryu, Jeong-Seon | - |
dc.contributor.author | Choi, Juwhan | - |
dc.contributor.author | Lee, Su Hwan | - |
dc.contributor.author | Ryu, Yon Ju | - |
dc.contributor.author | Lee, Jin Hwa | - |
dc.contributor.author | Chang, Jung Hyun | - |
dc.date.accessioned | 2021-12-04T16:00:15Z | - |
dc.date.available | 2021-12-04T16:00:15Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-01-11 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129397 | - |
dc.description.abstract | BackgroundEpidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation types are associated with efficacy of EGFR TKIs. We investigated the clinical outcomes of afatinib, erlotinib, and gefitinib according to EGFR mutation type in patients with lung adenocarcinoma.MethodsBetween May 2010 and December 2018, we investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations who received EGFR TKIs. Efficacies of EGFR TKIs such as response rate, progression-free survival (PFS), and overall survival (OS) were retrospectively evaluated according to exon 19 deletion (E19del), L858R point mutation (L858R) and uncommon mutations.ResultsThe frequency of E19del was 48.2%, that of L858R was 42.4%, and that of uncommon mutations was 9.4%. E19del and L858R were associated with superior PFS and OS compared with uncommon mutations. Erlotinib showed significantly inferior OS than other TKIs (30.8 3.3 in erlotinib vs. 39.1 +/- 4.3 in afatinib vs. 48.4 +/- 6.3 in gefitinib; p = 0.031) in patients with L858R. Gefitinib showed significantly inferior PFS (4.6 +/- 1.1 in gefitinib vs. 11.6 +/- 2.7 in afatinib vs. 10.6 +/- 2.7 in erlotinib; p = 0.049) in patients with uncommon mutations.Conclusion Afatinib was significantly associated with a longer PFS, presenting constant effectiveness in all EGFR mutation types. Caution may be needed on the use of erlotinib for L858R and the use of gefitinib for uncommon EGFR mutations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sung Yong | - |
dc.identifier.doi | 10.1186/s12885-020-07765-6 | - |
dc.identifier.scopusid | 2-s2.0-85099261379 | - |
dc.identifier.wosid | 000609592900006 | - |
dc.identifier.bibliographicCitation | BMC CANCER, v.21, no.1 | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.citation.title | BMC CANCER | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordAuthor | Epidermal growth factor receptor | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Adenocarcinoma | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.